Skip to content

Ceftaroline Diffusion Into Cerebrospinal Fluid of Children

Ceftaroline Diffusion Into Cerebrospinal Fluid of Children With Ventriculitis Due to Ventriculoperitoneal Shunt (VPS) Infection

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02600793
Enrollment
12
Registered
2015-11-09
Start date
2016-08-31
Completion date
2019-12-31
Last updated
2018-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrospinal Fluid Shunts, Ventriculoperitoneal Shunt

Brief summary

Ceftaroline fosamil is an intravenous (IV) drug that belongs to a group of antibiotics called cephalosporins . Antibiotics are drugs used to treat infections. Clinical studies in adults patient shave shown ceftaroline fosamil to be effective against many bacteria that are resistant to other currently approved antibiotics. Some of these bacteria may be responsible for infections in the central nervous system.The main aim of this study is to gather information to determine how much of a single IV dose of ceftaroline fosamil will enter into a child's CSF so that the benefit of giving ceftaroline fosamil to children with infections can be better determined.

Detailed description

Children 6 months to 17 years of age admitted to the hospital because of infected VPS (ventriculitis) will be eligible for the study. A total of twelve eligible patients will be included in the study. Eligible study subjects would be patients who have undergone VPS removal and placement of EVD tubing and are being treated with standard IV antibiotics for ventriculitis. CSF cultures are obtained before antibiotics treatment is initiated. Standard initial antibiotics regimen is usually IV ceftriaxone and vancomycin. The antibiotics regimen is subsequently adjusted based on the pathogen recovered from the CSF culture. Total IV antibiotic treatment is usually 14 days. Following clearance of the infection the patient undergoes new VPS insertion by neurosurgery service.

Interventions

Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected

Sponsors

Forest Laboratories
CollaboratorINDUSTRY
Basim Asmar
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 17 Years
Healthy volunteers
No

Inclusion criteria

* Age 6 months - 17 years * Ventriculitis due to VPS infection (abnormal CSF parameters consistent with meningeal inflammation and/or positive CSF culture) * VPS is externalized and External Ventriculostomy Drain (EVD) is in place * Patient has IV access and is receiving antibiotic treatment for VPS infection * Parent/Guardian signed written informed consent * Negative urine or serum pregnancy test for females of child-bearing potential

Exclusion criteria

* Known Allergy to beta-lactam antibiotics * Moderate to severe renal impairment (Creatinine clearance \< 50mL/minute) * Parent/Guardian written consent cannot be obtained * Positive urine or serum pregnancy test

Design outcomes

Primary

MeasureTime frameDescription
Pharmacokinetic assessment of Ceftaroline diffusion from blood into the Cerbrospinal fluid.8 hoursSerial collection of three blood and three cerbrospinal fluid sample over 8 hours

Countries

United States

Contacts

Primary ContactBasim Asmar, MD
basmar@wayne.edu313-745-5862

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026